SCHEDULE 13D/A: OrbiMed Advisors Increases Beneficial Ownership in Corvus Pharmaceuticals to 13.8% and Expands Warrant Exercise Blocker
Beneficial Ownership Update
OrbiMed Advisors and OrbiMed Capital GP V have filed an amendment to their Schedule 13D, disclosing an increased beneficial ownership of 13.8% in Corvus Pharmaceuticals, Inc. and an expanded warrant exercise limitation.
Summary
- OrbiMed Advisors LLC and OrbiMed Capital GP V LLC (collectively, the "Reporting Persons") filed Amendment No. 10 to their Statement on Schedule 13D regarding Corvus Pharmaceuticals, Inc.
- The amendment reports that the Reporting Persons' beneficial ownership of Corvus Pharmaceuticals' common stock has increased to approximately 13.8% of the outstanding shares.
- This increase in percentage of outstanding shares beneficially owned by the Reporting Persons is primarily due to a change in the total number of shares outstanding.
- The "Blocker," an exercise limitation on warrants held by the Reporting Persons, has been increased from 9.99% to 19.99%, allowing previously restricted warrants to become exercisable.
- As of the filing date, OrbiMed Private Investments V, LP (OPI V), whose general partner is GP V, beneficially owns 9,785,423 shares.
- This total includes pre-funded warrants to purchase 1,444,085 shares and common warrants to purchase 1,397,684 shares.
Sentiment
Score: 6
Explanation: The document is primarily a regulatory disclosure of an updated ownership stake and an increased warrant exercise limitation. This provides the reporting persons with greater flexibility, which is a neutral to slightly positive development for them, but does not contain direct positive or negative news about the issuer's performance or prospects.
Positives
- The increase of the "Blocker" from 9.99% to 19.99% provides OrbiMed with greater flexibility to exercise its warrants, potentially increasing its stake in Corvus Pharmaceuticals.
Future Outlook
The Reporting Persons intend to continuously review their investment in Corvus Pharmaceuticals based on various factors, including the Issuer's business, financial condition, and market conditions. They may acquire additional shares or other securities, or dispose of some or all of their currently owned shares, either in the open market or through privately negotiated transactions. No specific plans or proposals for extraordinary corporate transactions, changes in management, capitalization, or dividend policy have been formulated.
Industry Context
This filing is a routine disclosure by a significant institutional investor in a biotechnology company, reflecting an update to its ownership stake and related investment terms. It does not provide broader industry trends or competitive analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Warrant Exercise Limitation Adjustment | The 'Blocker' (exercise limitation prohibiting beneficial ownership above a certain percentage) on warrants held by the Reporting Persons was increased from 9.99% to 19.99%. This change allows the Reporting Persons to exercise warrants that were previously restricted. | 2024-05-06 | Increases the flexibility and potential for increased ownership by a significant institutional investor, potentially influencing future corporate actions or capital structure. |
Related Party Transactions
- OrbiMed Advisors LLC is the managing member of OrbiMed Capital GP V LLC, which is the general partner of OrbiMed Private Investments V, LP (OPI V). OPI V is the entity that directly holds the shares and warrants.
- Peter Thompson, a member of OrbiMed Advisors, has been a member of Corvus Pharmaceuticals' Board of Directors since November 2014. He is obligated to transfer any shares or economic benefits from stock options or equity awards received from Corvus to the Reporting Persons, who then provide them to OPI V.
Stakeholder Impact
- Shareholders: Increased transparency regarding a significant institutional investor's stake and its enhanced ability to exercise warrants. This could signal a long-term commitment or provide flexibility for future market actions by OrbiMed.
- Company (Corvus Pharmaceuticals): Awareness of a major investor's increased flexibility regarding its stake and potential for increased influence due to the higher 'Blocker' percentage.
Next Steps
- Reporting Persons will continue to review their investment in Corvus Pharmaceuticals.
- Reporting Persons may acquire additional shares or other securities of the Issuer.
- Reporting Persons may dispose of some or all of the shares currently owned or otherwise acquired.
Key Dates
| Date | Description |
|---|---|
| 2014-11-01 | Peter Thompson became a member of the Board of Directors of Corvus Pharmaceuticals, Inc. |
| 2016-04-01 | Original Statement on Schedule 13D filed by OrbiMed Advisors LLC and OrbiMed Capital GP V LLC. |
| 2018-01-26 | Amendment No. 1 to Schedule 13D filed. |
| 2018-03-14 | Amendment No. 2 to Schedule 13D filed. |
| 2019-07-02 | Amendment No. 3 to Schedule 13D filed. |
| 2020-02-03 | Issuer's Registration Statement on Form S-1 (SEC 333-236214) filed, referencing Pre-Funded Warrant to Purchase Shares of Common Stock. |
| 2020-04-17 | Amendment No. 4 to Schedule 13D filed. |
| 2021-02-17 | Amendment No. 5 to Schedule 13D filed. |
| 2021-08-04 | Amendment No. 6 to Schedule 13D filed. |
| 2021-09-22 | Amendment No. 7 to Schedule 13D filed. |
| 2021-11-03 | Amendment No. 8 to Schedule 13D filed. |
| 2024-05-06 | Issuer granted pre-funded warrants to purchase 1,444,085 shares and common warrants to purchase 1,397,684 shares to the Reporting Persons. Warrants became exercisable on or after this date. |
| 2024-05-08 | Amendment No. 9 to Schedule 13D filed. |
| 2025-04-25 | Issuer's Definitive Proxy Statement on Schedule 14A filed with the SEC, stating 68,169,461 outstanding shares. |
| 2025-04-29 | Date of event which requires the filing of Amendment No. 10 to Schedule 13D. |
| 2025-05-01 | Execution date of the Joint Filing Agreement and signing date of Amendment No. 10 to Schedule 13D. |
Keywords
Corvus Pharmaceuticals, OrbiMed Advisors, Schedule 13D, beneficial ownership, warrants, investment, SEC filing, biotechnology, pharmaceuticals, institutional investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.